Stay updated with breaking news from Advaxis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A number of firms have modified their ratings and price targets on shares of Advaxis (OTCMKTS: ADXS) recently: 4/4/2022 – Advaxis is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 4/1/2022 – Advaxis is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 3/26/2022 […]
StockNews.com started coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a research report report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock. ADXS stock opened at $0.11 on Friday. The firm has a 50 day moving average of $0.12 and a 200-day moving average of $0.28. […]
StockNews.com began coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report issued on Monday. The firm set a “sell” rating on the stock. Shares of ADXS opened at $0.12 on Monday. Advaxis has a 52 week low of $0.08 and a 52 week high of $0.79. Advaxis Company Profile (Get Rating) Advaxis, […]
/PRNewswire/ -- The "Cell and Gene Therapy World Market and Market Potential" report has been added to ResearchAndMarkets.com's offering. The report examines...
JERSEY CITY, N.J., March 23, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Head and Neck Cancer Market By Products (Abitrexate/